Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) announced a major managed Medicare agreement for TONMYA (cyclobenzaprine HCl sublingual tablets), adding approximately 9 million Medicare beneficiaries effective Jan. 1, 2027. Combined with previously announced commercial coverage agreements and broad Medicaid availability, the company said TONMYA will have pharmacy coverage reaching approximately 145 million covered lives, or 46% of the U.S. covered market, while discussions with additional commercial and Medicare payers continue.
This expansion marks a significant milestone for Tonix and for patients with fibromyalgia, a chronic condition characterized by widespread pain, fatigue, and cognitive difficulties. TONMYA, approved by the FDA in 2024, is the first new treatment for fibromyalgia in more than 15 years and is positioned as a first-in-class, non-opioid treatment option. The increased coverage means that nearly half of the U.S. insured population now has access to this therapy, potentially reducing reliance on opioids and other off-label treatments for fibromyalgia.
Following the expanded coverage and positive launch metrics, Tonix plans to add 50 sales representatives by mid-third quarter 2026, increasing its commercial sales force to approximately 150 people. The company said it is also expanding marketing and medical affairs initiatives to increase awareness of TONMYA. This aggressive commercial push underscores Tonix's commitment to establishing TONMYA as a standard of care for fibromyalgia, a market that has seen limited innovation for over a decade.
The implications of this coverage expansion are far-reaching. For patients, improved insurance access may reduce out-of-pocket costs and broaden treatment options. For healthcare providers, TONMYA offers a targeted, sublingual formulation of cyclobenzaprine, a muscle relaxant, designed to improve tolerability and efficacy. For Tonix, reaching 145 million covered lives strengthens its revenue potential and validates its commercial strategy. The company is also conducting Phase 2 clinical trials to evaluate TONMYA's potential in major depressive disorder and acute stress disorder, suggesting further applications beyond fibromyalgia.
Tonix Pharmaceuticals is a fully-integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. Beyond TONMYA, Tonix's CNS commercial infrastructure supports its acute migraine products, Zembrace SymTouch and Tosymra. The company's pipeline includes TNX-2900 for Prader-Willi syndrome, TNX-4800 for Lyme disease prophylaxis, and TNX-1500 for kidney transplant rejection prevention. For more details, visit the company’s newsroom at https://ibn.fm/TNXP.
This news matters because it represents a tangible improvement in patient access to a novel non-opioid therapy for a condition that affects an estimated 4 million adults in the U.S. As the healthcare industry continues to grapple with the opioid crisis, treatments like TONMYA offer a safer alternative for chronic pain management. The full press release is available at https://ibn.fm/tVAj3.
